Lineage Cell Therapeutics, Inc.
General ticker "LCTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $198.9M (TTM average)
Lineage Cell Therapeutics, Inc. follows the US Stock Market performance with the rate: 58.0%.
Estimated limits based on current volatility of 3.0%: low 1.64$, high 1.74$
Factors to consider:
- Total employees count: 77 (+2.7%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2022-12-31
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Manufacturing risks, Manufacturing disruptions, Product liability
- Current price 73.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.38$, 0.98$]
- 2025-12-31 to 2026-12-31 estimated range: [0.39$, 0.98$]
Financial Metrics affecting the LCTX estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.33 <= 0.04
- Positive: Shareholder equity ratio, % of 69.23 > 64.17
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.41 < Investing cash flow per share per price, % of -2.23
- Negative: negative Net income
Short-term LCTX quotes
Long-term LCTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $14.70MM | $8.95MM | $9.50MM |
| Operating Expenses | $37.22MM | $33.68MM | $30.98MM |
| Operating Income | $-22.52MM | $-24.73MM | $-21.48MM |
| Non-Operating Income | $-3.29MM | $1.45MM | $2.90MM |
| R&D Expense | $13.99MM | $15.71MM | $12.47MM |
| Income(Loss) | $-25.81MM | $-23.28MM | $-18.58MM |
| Taxes | $0.54MM | $-1.80MM | $0.00MM |
| Profit(Loss)* | $-26.27MM | $-21.49MM | $-18.61MM |
| Stockholders Equity | $73.34MM | $63.42MM | $78.38MM |
| Assets | $123.66MM | $101.02MM | $113.22MM |
| Operating Cash Flow | $1.06MM | $-28.57MM | $-23.09MM |
| Capital expenditure | $0.41MM | $0.67MM | $0.56MM |
| Investing Cash Flow | $-46.16MM | $46.45MM | $-2.31MM |
| Financing Cash Flow | $1.63MM | $6.42MM | $35.86MM |
| Earnings Per Share** | $-0.15 | $-0.12 | $-0.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.